AAPL344.66+5.16 (+1.52%) ▲|ABBV283.42-5.66 (-1.96%) ▼|ABT98.57-3.89 (-3.79%) ▼|ACN237.60-1.53 (-0.64%) ▼|ADBE255.28-1.45 (-0.56%) ▼|AMAT409.14+4.16 (+1.03%) ▲|AMD553.81+19.07 (+3.57%) ▲|AMGN437.33-1.61 (-0.37%) ▼|AMT178.95-4.61 (-2.51%) ▼|AMZN263.93+1.30 (+0.50%) ▲|AVGO338.58+4.21 (+1.26%) ▲|AXP323.66+5.32 (+1.67%) ▲|BA192.56+2.09 (+1.10%) ▲|BAC50.94+0.30 (+0.59%) ▲|BKNG158.82-5.10 (-3.11%) ▼|BLK1,142.09+13.41 (+1.19%) ▲|BMY60.82-0.87 (-1.40%) ▼|BNY146.54+2.29 (+1.59%) ▲|BRK-B542.08+2.26 (+0.42%) ▲|C123.61+1.10 (+0.90%) ▲|CAT741.55+16.31 (+2.25%) ▲|CL93.71-0.83 (-0.88%) ▼|CMCSA21.89-0.47 (-2.10%) ▼|COF208.30+6.74 (+3.34%) ▲|COP145.86-0.09 (-0.06%) ▼|COST996.30+1.69 (+0.17%) ▲|CRM242.29-0.14 (-0.06%) ▼|CSCO107.43+0.72 (+0.67%) ▲|CVS94.31-0.44 (-0.46%) ▼|CVX226.55+0.84 (+0.37%) ▲|DE632.65+0.45 (+0.07%) ▲|DHR230.57+6.33 (+2.82%) ▲|DIS111.38-0.29 (-0.26%) ▼|DUK121.06-0.28 (-0.23%) ▼|EMR164.95+4.49 (+2.80%) ▲|FDX299.55+0.79 (+0.26%) ▲|GD345.72+1.28 (+0.37%) ▲|GE298.48-1.39 (-0.46%) ▼|GEV928.88+38.55 (+4.33%) ▲|GILD153.46-3.05 (-1.95%) ▼|GM76.15-0.94 (-1.22%) ▼|GOOG330.45-5.95 (-1.77%) ▼|GOOGL334.59-5.69 (-1.67%) ▼|GS903.89+19.08 (+2.16%) ▲|HD314.43-0.68 (-0.22%) ▼|HON215.44+2.12 (+0.99%) ▲|IBM245.41+3.49 (+1.44%) ▲|INTC92.64+0.95 (+1.03%) ▲|INTU334.16-1.13 (-0.34%) ▼|ISRG429.84-8.16 (-1.86%) ▼|JNJ255.99-3.37 (-1.30%) ▼|JPM334.50-0.76 (-0.23%) ▼|KO92.67-0.82 (-0.88%) ▼|LIN502.06+0.17 (+0.03%) ▲|LLY1,270.37-13.29 (-1.04%) ▼|LMT548.75+0.04 (+0.01%) ▲|LOW196.54-0.75 (-0.38%) ▼|LRCX261.42-2.03 (-0.77%) ▼|MA623.34+2.92 (+0.47%) ▲|MCD245.86-0.66 (-0.27%) ▼|MDLZ62.47-1.53 (-2.38%) ▼|MDT93.52-1.11 (-1.17%) ▼|META707.79+13.54 (+1.95%) ▲|MMM174.01+2.64 (+1.54%) ▲|MO73.86-0.78 (-1.05%) ▼|MRK148.63+0.33 (+0.22%) ▲|MS184.97+4.57 (+2.53%) ▲|MSFT532.64+0.77 (+0.14%) ▲|MU917.85+21.78 (+2.43%) ▲|NEE78.69-0.18 (-0.22%) ▼|NFLX65.71-2.98 (-4.34%) ▼|NKE37.80-0.09 (-0.22%) ▼|NOW152.96+3.42 (+2.28%) ▲|NVDA221.37+4.90 (+2.26%) ▲|ORCL129.92-1.22 (-0.93%) ▼|PEP134.62+0.60 (+0.44%) ▲|PFE29.72-0.40 (-1.31%) ▼|PG157.73-1.59 (-1.00%) ▼|PLTR199.52+6.92 (+3.59%) ▲|PM196.84-3.07 (-1.53%) ▼|QCOM177.67+1.96 (+1.12%) ▲|RTX189.66-3.68 (-1.90%) ▼|SBUX98.74-0.64 (-0.64%) ▼|SCHW91.69+0.80 (+0.88%) ▲|SO90.53-0.18 (-0.20%) ▼|SPG206.14-0.85 (-0.41%) ▼|T21.96-1.46 (-6.23%) ▼|TMO694.24+6.87 (+1.00%) ▲|TMUS153.10-4.65 (-2.95%) ▼|TSLA386.45+12.74 (+3.41%) ▲|TXN288.23+10.45 (+3.76%) ▲|UBER68.23-0.72 (-1.04%) ▼|UNH417.32-1.94 (-0.46%) ▼|UNP289.18+1.57 (+0.55%) ▲|UPS100.18+1.66 (+1.68%) ▲|USB59.35+0.26 (+0.44%) ▲|V408.62+2.05 (+0.50%) ▲|VZ43.48-1.07 (-2.39%) ▼|WFC82.31+0.11 (+0.13%) ▲|WMT117.74-0.11 (-0.09%) ▼|XOM177.70-0.17 (-0.09%) ▼|AAPL344.66+5.16 (+1.52%) ▲|ABBV283.42-5.66 (-1.96%) ▼|ABT98.57-3.89 (-3.79%) ▼|ACN237.60-1.53 (-0.64%) ▼|ADBE255.28-1.45 (-0.56%) ▼|AMAT409.14+4.16 (+1.03%) ▲|AMD553.81+19.07 (+3.57%) ▲|AMGN437.33-1.61 (-0.37%) ▼|AMT178.95-4.61 (-2.51%) ▼|AMZN263.93+1.30 (+0.50%) ▲|AVGO338.58+4.21 (+1.26%) ▲|AXP323.66+5.32 (+1.67%) ▲|BA192.56+2.09 (+1.10%) ▲|BAC50.94+0.30 (+0.59%) ▲|BKNG158.82-5.10 (-3.11%) ▼|BLK1,142.09+13.41 (+1.19%) ▲|BMY60.82-0.87 (-1.40%) ▼|BNY146.54+2.29 (+1.59%) ▲|BRK-B542.08+2.26 (+0.42%) ▲|C123.61+1.10 (+0.90%) ▲|CAT741.55+16.31 (+2.25%) ▲|CL93.71-0.83 (-0.88%) ▼|CMCSA21.89-0.47 (-2.10%) ▼|COF208.30+6.74 (+3.34%) ▲|COP145.86-0.09 (-0.06%) ▼|COST996.30+1.69 (+0.17%) ▲|CRM242.29-0.14 (-0.06%) ▼|CSCO107.43+0.72 (+0.67%) ▲|CVS94.31-0.44 (-0.46%) ▼|CVX226.55+0.84 (+0.37%) ▲|DE632.65+0.45 (+0.07%) ▲|DHR230.57+6.33 (+2.82%) ▲|DIS111.38-0.29 (-0.26%) ▼|DUK121.06-0.28 (-0.23%) ▼|EMR164.95+4.49 (+2.80%) ▲|FDX299.55+0.79 (+0.26%) ▲|GD345.72+1.28 (+0.37%) ▲|GE298.48-1.39 (-0.46%) ▼|GEV928.88+38.55 (+4.33%) ▲|GILD153.46-3.05 (-1.95%) ▼|GM76.15-0.94 (-1.22%) ▼|GOOG330.45-5.95 (-1.77%) ▼|GOOGL334.59-5.69 (-1.67%) ▼|GS903.89+19.08 (+2.16%) ▲|HD314.43-0.68 (-0.22%) ▼|HON215.44+2.12 (+0.99%) ▲|IBM245.41+3.49 (+1.44%) ▲|INTC92.64+0.95 (+1.03%) ▲|INTU334.16-1.13 (-0.34%) ▼|ISRG429.84-8.16 (-1.86%) ▼|JNJ255.99-3.37 (-1.30%) ▼|JPM334.50-0.76 (-0.23%) ▼|KO92.67-0.82 (-0.88%) ▼|LIN502.06+0.17 (+0.03%) ▲|LLY1,270.37-13.29 (-1.04%) ▼|LMT548.75+0.04 (+0.01%) ▲|LOW196.54-0.75 (-0.38%) ▼|LRCX261.42-2.03 (-0.77%) ▼|MA623.34+2.92 (+0.47%) ▲|MCD245.86-0.66 (-0.27%) ▼|MDLZ62.47-1.53 (-2.38%) ▼|MDT93.52-1.11 (-1.17%) ▼|META707.79+13.54 (+1.95%) ▲|MMM174.01+2.64 (+1.54%) ▲|MO73.86-0.78 (-1.05%) ▼|MRK148.63+0.33 (+0.22%) ▲|MS184.97+4.57 (+2.53%) ▲|MSFT532.64+0.77 (+0.14%) ▲|MU917.85+21.78 (+2.43%) ▲|NEE78.69-0.18 (-0.22%) ▼|NFLX65.71-2.98 (-4.34%) ▼|NKE37.80-0.09 (-0.22%) ▼|NOW152.96+3.42 (+2.28%) ▲|NVDA221.37+4.90 (+2.26%) ▲|ORCL129.92-1.22 (-0.93%) ▼|PEP134.62+0.60 (+0.44%) ▲|PFE29.72-0.40 (-1.31%) ▼|PG157.73-1.59 (-1.00%) ▼|PLTR199.52+6.92 (+3.59%) ▲|PM196.84-3.07 (-1.53%) ▼|QCOM177.67+1.96 (+1.12%) ▲|RTX189.66-3.68 (-1.90%) ▼|SBUX98.74-0.64 (-0.64%) ▼|SCHW91.69+0.80 (+0.88%) ▲|SO90.53-0.18 (-0.20%) ▼|SPG206.14-0.85 (-0.41%) ▼|T21.96-1.46 (-6.23%) ▼|TMO694.24+6.87 (+1.00%) ▲|TMUS153.10-4.65 (-2.95%) ▼|TSLA386.45+12.74 (+3.41%) ▲|TXN288.23+10.45 (+3.76%) ▲|UBER68.23-0.72 (-1.04%) ▼|UNH417.32-1.94 (-0.46%) ▼|UNP289.18+1.57 (+0.55%) ▲|UPS100.18+1.66 (+1.68%) ▲|USB59.35+0.26 (+0.44%) ▲|V408.62+2.05 (+0.50%) ▲|VZ43.48-1.07 (-2.39%) ▼|WFC82.31+0.11 (+0.13%) ▲|WMT117.74-0.11 (-0.09%) ▼|XOM177.70-0.17 (-0.09%) ▼|
14.6 C
New York
Wednesday, October 21, 2026

Tag: weight loss

newsFORsourcecompanycontentinformation1releasesmarket

Atrogi announces Cell paper highlighting transformative potential of muscle-targeted therapy in metabolic disease

Atrogi's breakthrough discovery enables chronic use of next-generation, highly selective β2-agonists for the first time in metabolic diseaseFirst-in-class oral therapy ATR-258 mimics the effects...

CagriSema Demonstrates Significant Weight Loss in Adults with Obesity

Once-weekly medication results in weight loss of up to 22.7% in adults without diabetes and 15.7% in those with type 2 diabetes CHICAGO, June 22,...

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published...

Bagsværd, Denmark, 22 June – Today, The New England Journal of Medicine (NEJM) published results from Novo Nordisk’s phase 3 REDEFINE 1 trial evaluating the efficacy and safety of investigational CagriSema plus lifestyle interventions for weight loss in adults with obesity or overweight who have a weight-related medical complication and without diabetes.1 REDEFINE 1 met its co-primary endpoints and achieved statistically significant and clinically meaningful weight loss at 68 weeks in patients taking CagriSema versus placebo.1 These data, along with the related phase 3 REDEFINE 2 study conducted in adults with overweight or obesity and type 2 diabetes, were presented today during a scientific symposium at the American Diabetes Association’s (ADA) 85th Scientific Sessions and published in NEJM.

CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM

Data presented simultaneously at the American Diabetes Association's® 85th Scientific Sessions, showed mean weight reduction in the highest range of efficacy observed with existing...

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits observed in combination with incretin therapy

Nixol Capsules Launch in the UK: A Natural Path to Weight Management and Metabolic Support

Nixol introduces a new natural supplement in the United Kingdom to support metabolism, curb cravings, and promote healthy weight loss management using vegan-friendly ingredients. 
Nixol introduces a new natural supplement in the United Kingdom to support metabolism, curb cravings, and promote healthy weight loss management using vegan-friendly ingredients.

Lilly’s oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The...

The investigational once-daily pill lowered A1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as four weeks, in adults...

MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA’s 85th Scientific Session

CAMBRIDGE, Mass., June 21, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation of...

Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more...

Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA

Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025

Bagsværd, Denmark, 20 June 2025 – Novo Nordisk announces subcutaneous amycretin data being presented at the American Diabetes Association (ADA) 85th Scientific Sessions in Chicago, US.1 Full results of two clinical trials evaluating the safety, tolerability and weight loss potential of subcutaneous and oral amycretin in people with overweight or obesity were published today in The Lancet medical journal.1,3 Amycretin is the first treatment that combines GLP-1 and amylin receptor agonism biology in a single molecule.

Water Instead of Diet Drinks Associated with Two-Fold Rate of Diabetes Remission in Women

New Research Demonstrates Significant Benefits of Simple Dietary Switch for Blood Glucose Control and Long-Term Weight Management CHICAGO, June 20, 2025 /PRNewswire/ -- Consistently replacing...

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin...

SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced two upcoming late-breaking poster presentations at the American Diabetes Association 85th Scientific Sessions, being held from June 20-23 in Chicago, IL.

Novo Nordisk advances early-stage obesity medication, amycretin, to phase 3 clinical development based on early-phase clinical trial results in people with obesity or excess...

Both subcutaneous and oral formulations will advance straight to phase 3 development based on completed clinical studies and feedback received from regulatory authorities1,2PLAINSBORO, N.J.,...

Cirius Therapeutics Announces Positive Data for MPC Inhibitor 0602K Alone and in Combination with Tirzepatide

MPC-inhibitor 0602K shows significant preservation of lean mass & increased muscle function combined with tirzepatide in pre-clinical DIO models0602K shows profound beneficial transformation of...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsWeight loss

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers